尼普地洛(Nipradilol) - 药物靶点：β-adrenoceptors_在研适应症：青光眼，高眼压症，心绞痛_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Nipradilol (JAN/INN)

+ [3]

靶点

β-adrenoceptors

作用方式

拮抗剂

作用机制

β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂)

治疗领域

神经系统疾病心血管疾病眼部疾病+ [1]

在研适应症

青光眼高眼压症心绞痛+ [1]

非在研适应症-

原研机构-

在研机构

Teika Pharmaceutical Co., Ltd.

Kowa Co., Ltd.

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

日本 (1988-09-20),

心绞痛高血压

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C15H22N2O6

InChIKeyOMCPLEZZPVJJIS-UHFFFAOYSA-N

CAS号81486-22-8

关联

3

项与尼普地洛相关的临床试验

JPRN-UMIN000011778

/ CompletedN/AIIT

Therapeutic outcome of unoprostone and nipradilol in patients with normal tension glaucoma. - Therapeutic outcome of unoprostone and nipradilol

开始日期2011-07-01

申办/合作机构-

JPRN-UMIN000006820

/ CompletedN/AIIT

Neuroprotective efficacy of topical unoprostone isopropyl or nipradilol in patients with retinitis pigmentosa - Neuroprotective efficacy of topical unoprostone isopropyl or nipradilol in patients with retinitis pigmentosa

开始日期2009-02-01

申办/合作机构-

JPRN-C000000422

/ Completed临床4期

Randomized double blind comparative study of nipradilol, an alfa-1,beta-blocker with a nitric oxide donative action, and timolol, a non-selective beta-blocker, on the visual field in Japanese patients with normal-tension glaucoma. - Japanese Normal Tension Glaucoma Treatment Study (JNTGTS)

开始日期2002-04-01

申办/合作机构

Kowa Co., Ltd.

100 项与尼普地洛相关的临床结果

登录后查看更多信息

100 项与尼普地洛相关的转化医学

登录后查看更多信息

100 项与尼普地洛相关的专利（医药）

登录后查看更多信息

295

项与尼普地洛相关的文献（医药）

2025-01-01·Clinical & Experimental Ophthalmology

Comparative analysis of medical treatments for long‐term control of normal tension glaucoma: A systematic review and model‐based network meta‐analysis

Review

作者: Chen, Chun‐Yi ; Lin, Chun‐Ju ; Yang, Ting‐Kai ; Ju, Yuh‐Jen ; Kuo, Hou‐Ting ; Lee, Chien‐Chang ; Chen, Wen‐Hsien ; Wu, Albert Y. ; Ho, Jennifer Hui‐Chun

AbstractBackgroundTo evaluate and compare the long‐term efficacy of medical treatments for normal tension glaucoma (NTG) in controlling intraocular pressure (IOP), and establish a hierarchical ranking based on their effectiveness. ‘Long‐term’ is defined as a treatment duration of over 12 weeks in randomised controlled trials (RCTs).MethodsThis systematic review and model‐based network meta‐analysis (MBNMA) collected data of 795 patients with 997 eyes from RCTs. Patients with NTG were selected based on strict inclusion/exclusion criteria, with randomsation procedures and masking as reported in the individual trials. Eight different medications were compared, including prostaglandin analogues, beta‐blockers, brimonidine, unoprostone isopropyl, brovincamine, and palmitoylethanolamide (PEA). Notably, PEA is an oral medication, while other drugs are topical agents.ResultsPrimary outcome is the long‐term efficacy of IOP control across medications with different follow‐up durations. Among the eight medications, PEA demonstrates the highest efficacy (Surface under the cumulative ranking, SUCRA = 7.46%), followed by two prostaglandin analogues: travoprost (SUCRA = 6.86%) and latanoprost (SUCRA = 6.76%), then two beta‐blockers: nipradilol (SUCRA = 4.90%) and timolol (SUCRA = 4.89%). Both brimonidine and unoprostone isopropyl have SUCRA scores below 4.0%, indicating modest but limited efficacy. Brovincamine has the lowest SUCRA score (1.32%), reflecting minimal effectiveness.ConclusionsThis study revealed PEA as a promising agent for long‐term IOP control in NTG patients, suggesting potential use as primary or adjunctive therapy. The outcomes call for PEA's consideration in clinical practice and highlight the need for further research into its long‐term efficacy and safety for NTG.

2024-02-01·Advances in Therapy

The Effect of β-Blocker Eye Drops on Pulse Rate, Ocular Blood Flow, and Glaucoma Progression: A Retrospective Longitudinal Study

Article

作者: Kiyota, Naoki ; Omodaka, Kazuko ; Shiga, Yukihiro ; Yokoyama, Yu ; Nakazawa, Toru ; Himori, Noriko ; Pak, Kyongsun ; Ninomiya, Takahiro ; Tsuda, Satoru

INTRODUCTIONOur study was conducted to determine factors associated with the effectiveness of a β-blocker eye drop add-on in altering pulse rate (PR) in glaucoma patients.METHODSThis retrospective study examined 236 eyes of 138 patients who received a β-blocker eye drop add-on during follow-up. Patients were included if at least one PR measurement was available both before and after the add-on was started. We collected data on ophthalmic parameters: longitudinal PR; longitudinal choroidal blood flow, represented by laser speckle flowgraphy-measured mean blur rate (MBR); and diacron-reactive oxygen metabolites (d-ROMs). We used a multivariable linear mixed-effects model to investigate the effectiveness of the β-blocker eye drop add-on in altering PR and examined factors contributing to a larger PR alteration after the add-on was started by analyzing the effect on PR of the interaction term between the add-on and clinical factors. We used the k-means method to classify the patients.RESULTSThe β-blocker eye drop add-on reduced PR (- 7.61 bpm, P < 0.001). Female gender, higher PR when the add-on was started, lower central corneal thickness, and a higher d-ROM level were associated with greater reduction in PR (P < 0.05). In a cluster of patients with these clinical features, choroidal MBR increased by + 3.42% when we adjusted for change over time; MD slope, which represents the speed of glaucoma progression, improved by + 0.64 dB/year (P < 0.05).CONCLUSIONSWe identified a glaucoma subgroup in which PR decreased, choroidal blood flow increased, and glaucoma progression slowed after a β-blocker eye drop add-on was started.

2022-06-27·Reviews in Inorganic Chemistry

NO, CO and H₂S based pharmaceuticals in the mission of vision (eye health): a comprehensive review

作者: Khan, Mohd Washid ; Maurya, Ram Charitra ; Mir, Jan Mohammad

AbstractA set of well defined signaling molecules responsible for normal functioning of human physiology including nitric oxide along with carbon monoxide and hydrogen sulphide are referred as “gasotransmitters”. Due to their involvement in almost every system of a human body, the care of highly sensitive organs using these molecules as drugs represents highly fascinating area of research. In connection with these interesting aspects, the applied aspects of these gaseous molecules in maintaining healthy eye and vision have been targeted in this review. Several examples of eye-droppers including NORMs like latanoprost and nipradiol, CORMs like CORM-3 and CORM-A1, and Hydrogen sulfide releasing system like GYY4137 have been discussed in this context. Therefore the relation of these trio-gasotransmitters with the ophthalmic homeostasis on one hand, and de-infecting role on the other hand has been mainly highlighted. Some molecular systems capable of mimicking gasotransmitter action have also been introduced in connection with the titled theme.

100 项与尼普地洛相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01691	尼普地洛	S01EA	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
青光眼	日本	Teika Pharmaceutical Co., Ltd.	1996-06-16
高眼压症	日本	Teika Pharmaceutical Co., Ltd.	1996-06-16
心绞痛	日本	Kowa Co., Ltd.	1988-09-20
高血压	日本	Kowa Co., Ltd.	1988-09-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ARVO2011	N/A	-	8	Topical Nipradilol	(淵餘窪壓壓齋繭壓淵鹽) = 網衊齋繭醖淵衊鹹夢衊襯窪簾鏇簾網廠壓網鏇 (憲鏇願艱選積糧艱簾淵 ) 更多	-	2011-04-01
ARVO2004	N/A	糖尿病性视网膜病变	-	Nipradilol-treated eyes	(製獵鬱淵醖壓蓋繭網糧) = 遞廠衊糧範憲網蓋壓鏇鑰構鑰艱積鏇遞衊蓋醖 (選鏇積獵壓獵衊衊遞獵 )	-	2004-05-01
				topical nipradilol (Non-treated eyes)	(製獵鬱淵醖壓蓋繭網糧) = 衊願壓窪積餘蓋觸艱糧鑰構鑰艱積鏇遞衊蓋醖 (選鏇積獵壓獵衊衊遞獵 )
ARVO2002	N/A	-	-	Nipradilol (1%)	(鏇醖繭壓醖膚觸夢糧餘) = 齋醖製築觸艱鏇襯選襯襯醖艱醖積齋夢鹹選獵 (膚築築鹹蓋製衊齋醖膚 )	积极	2002-12-01
				Timolol (0.5%) and Bunazosin (0.125%)	(鏇醖繭壓醖膚觸夢糧餘) = 觸壓鹹糧選襯鏇選網鑰襯醖艱醖積齋夢鹹選獵 (膚築築鹹蓋製衊齋醖膚 )